abstract |
Disclosed is the use of a CD20 antibody in the manufacture of a medicament for the treatment of Sj÷grenÆs syndrome, wherein the medicament is formulated for concurrent or consecutive administration with an anti-malarial agent medicament, and wherein said antibody and anti-malarial agent medicament when administered to a patient provide at least about 30% improvement over baseline in two or more of dryness, fatigue and joint pain on a Visual Analogue Scale. |